Tissue diagnostics is a key enabler of personalized medicine. The increasing number of cancer cases multiplied by the growing number of tests required per patient exploded the need for such tests. However, current slow and inefficient technologies cannot answer this need.

Who is Lunaphore? We build laboratory automation systems for tissue diagnostics, based on a unique microfluidic technology. Our mission is to disrupt the field by fundamentally changing the time & resource driven nature of tissue biomarker tests.

We bring technology breakthrough
- 10 to 20x faster assays
- Highly scalable
- 9 years of R&D at Swiss Institute of Technology

Fastest system for tissue diagnostics
Shortest turn-around-time
- 30 min vs. 3h30 market leader
- >2x lab productivity: a patient case in 2 hours

Highest throughput
- 5x compared to market leader
- 5 to 10x less equipment is needed

Best assay automation technology
Medical Value
- Unique quantitative staining

Highest quality assays
- Reproducible and uniform assays with definitive border
- No oil, coverglass or cross-contamination.

High-growth market
The tissue diagnostics market is projected to double within the next 5 years due to an increasing need for personalized medicine.

LUNAPHORE TECHNOLOGIES SA
EPFL Innovation Park, Batiment C
1015 Lausanne, Switzerland.
www.lunaphore.com
contact@lunaphore.com
+41 21 353 58 10

FOUNDERS
Dr. Ata Tuna Ciftlik, CEO, Chairman
- 10+ years exp. in biomedical microsystems development
- >20 publications & 6 patents

Dr. Diego G. Dupouy, CTO
- 6+ years exp. in microfluidic diagnostic systems
- 12 publications & 3 patents
- Previously at IBM Research California

Déborah Heintze, COO
- 4+ years experience
- Bioengineer EPFL & Harvard-MIT division of health sciences
- Previously at EPFL Tech Transfer

TEAM STATISTICS
Core Team
- 14 FTEs: 60 years combined experience
- 5 PhDs, 8 MSc.

Collaborative Research Team
- 5 FTEs: 3 Post-Docs, 2 PhD students

Advisory Board & Consultants
- 6 Advisors - 100+ years combined exp.
- Manufacturing, Sales & Marketing, Finance, Pathology
- 4 Consultants - 50+ years combined exp.
- Regulatory, Legal, IP, and Management

IP & CLINICAL DATA
4 patents & 2 trademarks
Microfluidic tissue processor is protected by portfolio of 4 patents.

Clinical Data
Published data with 100+ patients
3 Publications in top-notch journals
Field Tested
With 200+ cases at 10 different sites.

FINANCIALS
Raised so far
- CHF 6M
- Now closing CHF 3.7 M 2017Q1
Open
- Series B CHF 10 M 2018Q2

Visit us at www.lunaphore.com